Low-Sodium Oxybate Remains Effective, Safe in Narcolepsy With Psychiatric and Neurologic Comorbidities
Results from a post-hoc analysis of the pivotal phase 3 trial (NCT03030599) for which low-sodium oxybate (Xywav; Jazz Pharmaceuticals) was approved on showed that treatment with the medication resulted in similar effectiveness and safety among patients …